JP2012529279A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529279A5
JP2012529279A5 JP2012514491A JP2012514491A JP2012529279A5 JP 2012529279 A5 JP2012529279 A5 JP 2012529279A5 JP 2012514491 A JP2012514491 A JP 2012514491A JP 2012514491 A JP2012514491 A JP 2012514491A JP 2012529279 A5 JP2012529279 A5 JP 2012529279A5
Authority
JP
Japan
Prior art keywords
linkage
nucleotides
phosphorothioate
nucleotide analogs
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514491A
Other languages
English (en)
Other versions
JP2012529279A (ja
Filing date
Publication date
Priority claimed from PCT/EP2009/067561 external-priority patent/WO2010076248A1/en
Application filed filed Critical
Priority claimed from PCT/EP2010/058278 external-priority patent/WO2010142805A1/en
Publication of JP2012529279A publication Critical patent/JP2012529279A/ja
Publication of JP2012529279A5 publication Critical patent/JP2012529279A5/ja
Pending legal-status Critical Current

Links

Description

ヌクレオチド間の連結
用語「連結基」または「ヌクレオチド間連結」は、2つのヌクレオチド、2つのヌクレオチドアナログ、およびヌクレオチドおよびヌクレオチドアナログ等を一緒に共有結合させることができる基を意味すると意図される。特定かつ好ましい例には、リン酸基およびホスホロチオエート基が含まれる。
本明細書中で提供されるものとして、好適な硫黄(S)を含むヌクレオチド間連結が好ましい。ホスホロチオエートヌクレオチド間連結もまた、ギャップマーのギャップ領域(B)にとって特に好ましい。また、ホスホロチオエート連結を、フランキング領域(AおよびC、ならびにAまたはCをDに連結するため、および必要に応じて領域D内の)に使用することもできる。
JP2012514491A 2009-06-12 2010-06-14 新規の強力な抗ａｐｏｂアンチセンス化合物 Pending JP2012529279A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18638809P 2009-06-12 2009-06-12
US61/186,388 2009-06-12
US25309009P 2009-10-20 2009-10-20
US61/253,090 2009-10-20
EPPCT/EP2009/067561 2009-12-18
PCT/EP2009/067561 WO2010076248A1 (en) 2008-12-31 2009-12-18 Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
PCT/EP2010/058278 WO2010142805A1 (en) 2009-06-12 2010-06-14 New potent anti apob antisense compounds

Publications (2)

Publication Number Publication Date
JP2012529279A JP2012529279A (ja) 2012-11-22
JP2012529279A5 true JP2012529279A5 (ja) 2013-08-01

Family

ID=42541569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514491A Pending JP2012529279A (ja) 2009-06-12 2010-06-14 新規の強力な抗ａｐｏｂアンチセンス化合物

Country Status (12)

Country Link
US (1) US9290758B2 (ja)
EP (1) EP2440215B1 (ja)
JP (1) JP2012529279A (ja)
CN (1) CN102802637A (ja)
AU (1) AU2010258570B2 (ja)
BR (1) BR112012000214A2 (ja)
CA (1) CA2764822A1 (ja)
ES (1) ES2555057T3 (ja)
IL (1) IL216519A0 (ja)
MX (1) MX2011013078A (ja)
NZ (1) NZ596608A (ja)
WO (1) WO2010142805A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
DK2951305T3 (en) 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
CN112263682A (zh) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物
JP2017501684A (ja) * 2013-11-14 2017-01-19 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Ａｐｏｂアンチセンスコンジュゲート化合物
SG11202007652UA (en) * 2018-02-21 2020-09-29 Bristol Myers Squibb Co Camk2d antisense oligonucleotides and uses thereof
CA3117981A1 (en) * 2018-11-13 2020-05-22 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-10b activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
EP1523348B1 (en) * 2002-07-19 2011-03-30 Medela Holding AG Connector device
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7687617B2 (en) 2002-11-18 2010-03-30 Santaris Pharma A/S Oligonucleotides with alternating segments of locked and non-locked nucleotides
WO2004080406A2 (en) * 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
AU2004229519B2 (en) * 2003-04-09 2011-07-21 Alnylam Pharmaceuticals, Inc. iRNA conjugates
EP2199298A1 (en) * 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
JP2009507499A (ja) * 2005-09-15 2009-02-26 サンタリス ファーマ アー／エス Ａｐｏ−ｂ１００発現の抑制のためのｒｎａアンタゴニスト化合物
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
AU2007229161B2 (en) 2006-03-23 2012-07-12 Roche Innovation Center Copenhagen A/S Small internally segmented interfering RNA
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
AU2007296055A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
EP2090127A2 (en) 2006-10-30 2009-08-19 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs

Similar Documents

Publication Publication Date Title
JP2012529279A5 (ja)
WO2011072246A3 (en) Tal effector-mediated dna modification
ES2568803T3 (es) Reducción del contenido de ácidos grasos saturados en semillas de plantas
SG161260A1 (en) Methods for treating infectious disease exacerbated asthma
WO2011139699A3 (en) 5' modified nucleosides and oligomeric compounds prepared therefrom
FR2936102B1 (fr) Procede de preparation d'un materiau composite silicium/ carbone, materiau ainsi prepare et electrode notamment electrode negative, comprenant ce materiau.
JP2008245635A5 (ja)
WO2010135836A8 (en) Novel beta-glucosidase enzymes
WO2011139695A3 (en) Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
WO2012166471A3 (en) Hydrocarbon transformations using carbocatalysts
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2009114089A3 (en) Using fullerenes to enhance and stimulate hair growth
WO2010046493A3 (en) Gene transfer vectors comprising at least one isolated dna molecule having insulator and or boundary properties and methods to identify the same
FR2937566B1 (fr) Catalyseur d'hydrogenation, notamment de sulfure de carbone
WO2012090194A3 (en) Compositions and methods for treating a skin disorder
ATE536360T1 (de) Neues nukleinsäuretransfersystem
WO2009150374A3 (fr) Fibres a conductivite electrique pour systemes bioelectrochimiques, electrodes realisees avec de telles fibres et systemes comportant une ou plusieurs de telles electrodes
WO2009027527A3 (en) Rna antagonist compounds for the modulation of fabp4/ap2
JP2009143907A5 (ja)
WO2015044890A3 (en) Tools and methods using mirna 182, 96 and/or 183 for treating pathologies
RU2009133894A (ru) Амфифильная высокополимерная рнк из пекарских дрожжей
WO2011005363A3 (en) Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
Lee A Study on the Problems and Improvements of BTL Project Process
CN202627122U (zh) 皮搋子